Guardant Health (GH) announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology, ACG, 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant Health’s 2023 ACG abstract, a study of an expanded cohort of 20,000 patients confirmed findings from earlier reports on the effectiveness of the Shield blood-based screening test in improving adherence to colorectal cancer, CRC, screening. Shield is the first and only blood test to receive FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. The findings demonstrated an over 90% adherence rate for Shield, tracking well above average screening adherence for overall CRC testing which ranges from 28-71%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $90 from $60 at Piper Sandler
- Tempus AI price target raised to $105 from $70 at Piper Sandler
- EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Guardant Health price target raised to $70 from $60 at Barclays